Minerva Neurosciences grants 12,147 stock options

Minerva Neurosciences, Inc. reported that director Inderjit Kaul received a grant of 12,147 stock options to purchase common stock at an exercise price of $3.97 per share, expiring on August 2, 2036.

Rhea-AI Filing Summary

Minerva Neurosciences, Inc. reported that director Inderjit Kaul received a grant of 12,147 stock options to purchase common stock at an exercise price of $3.97 per share, expiring on August 2, 2036. All 12,147 options are reported as directly held after the grant.

Vesting is performance- and time-based: 25% vests on November 14, 2026; 45% vests on the tenth day after a public announcement that a Phase 3 confirmatory trial of roluperidone in schizophrenia met its primary endpoint at 12 weeks; and the remaining 30% vests on the tenth day after public announcement of safety data from the 40-week relapse assessment phase, in each case while Kaul provides services under a consulting agreement dated November 14, 2025.

Insider Trade Summary

Grant/Award: 12,147 shares

Grant/Award 1 txn

Insider Kaul Inderjit

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	12,147	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 12,147 contracts (Direct)

Footnotes (1)

1. F1. 25% of the option shall vest on November 14, 2026; an additional 45% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date.

Key Figures

Options granted: 12147.0000 options Exercise price: $3.9700 per share Expiration date: 2036-08-02 +3 more

6 metrics

Options granted 12147.0000 options Stock Option (right to buy) granted to director Inderjit Kaul

Exercise price $3.9700 per share Exercise price for the stock options on Minerva common stock

Expiration date 2036-08-02 Option expiration date for the granted stock options

Time-based vesting portion 25% Vests on November 14, 2026, subject to continued consulting services

Primary endpoint vesting portion 45% Vests after public announcement that Phase 3 roluperidone trial met primary endpoint

Safety data vesting portion 30% Vests after public announcement of safety data from 40-week relapse assessment phase

Key Terms

Stock Option (right to buy), Phase 3 confirmatory trial, primary endpoint, relapse assessment phase, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Phase 3 confirmatory trial medical

"primary endpoint of its Phase 3 confirmatory trial of roluperidone"

primary endpoint medical

"that it has achieved, on a statistically significant basis, the primary endpoint"

The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.

relapse assessment phase medical

"safety data from the 40-week relapse assessment phase"

consulting agreement financial

"services pursuant to that certain consulting agreement dated November 14, 2025"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option grant did Minerva Neurosciences (NERV) report for Inderjit Kaul?

Minerva Neurosciences reported a grant of 12,147 stock options to director Inderjit Kaul at an exercise price of $3.97 per share, expiring on August 2, 2036. All options relate to the company’s common stock and are reported as directly held.

How do the new NERV stock options for Inderjit Kaul vest?

The options vest in three tranches: 25% on November 14, 2026; 45% on the tenth day after a public announcement that a Phase 3 roluperidone trial met its primary endpoint; and 30% after a public announcement of 40-week safety data.

What performance conditions affect Inderjit Kaul’s Minerva Neurosciences (NERV) option vesting?

Two tranches are tied to clinical milestones: 45% vests after a public announcement that a Phase 3 confirmatory trial of roluperidone in schizophrenia achieved its primary endpoint, and 30% vests after a public announcement of safety data from the 40-week relapse assessment phase.

Is continued service required for Inderjit Kaul’s NERV options to vest?

Yes. Each vesting event is conditioned on Kaul providing services under a consulting agreement dated November 14, 2025 on the applicable vesting date. If he is not providing services then, the related tranche does not vest under these terms.

What is the exercise price and term of the Minerva Neurosciences (NERV) options granted?

The granted options have an exercise price of $3.97 per share and an expiration date of August 2, 2036. This gives a multi-year window to exercise any portion that becomes vested under the time- and performance-based conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 06:05 PM Accepted by SEC EDGAR 08/03/2026 - 06:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaul Inderjit

(Last) (First) (Middle)

C/O MINERVA NEUROSCIENCES, INC.

1500 DISTRICT AVENUE

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Minerva Neurosciences, Inc. [ NERV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.97	08/03/2026		A		12,147		(1)	08/02/2036	Common Stock	12,147	$0	12,147	D

Explanation of Responses:

1. 25% of the option shall vest on November 14, 2026; an additional 45% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date.

	/s/ Frederick Ahlholm, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)